- Open Access
Evaluation of three high abundance protein depletion kits for umbilical cord serum proteomics
© Liu et al; licensee BioMed Central Ltd. 2011
- Received: 8 December 2010
- Accepted: 9 May 2011
- Published: 9 May 2011
High abundance protein depletion is a major challenge in the study of serum/plasma proteomics. Prior to this study, most commercially available kits for depletion of highly abundant proteins had only been tested and evaluated in adult serum/plasma, while the depletion efficiency on umbilical cord serum/plasma had not been clarified. Structural differences between some adult and fetal proteins (such as albumin) make it likely that depletion approaches for adult and umbilical cord serum/plasma will be variable. Therefore, the primary purposes of the present study are to investigate the efficiencies of several commonly-used commercial kits during high abundance protein depletion from umbilical cord serum and to determine which kit yields the most effective and reproducible results for further proteomics research on umbilical cord serum.
The immunoaffinity based kits (PROTIA-Sigma and 5185-Agilent) displayed higher depletion efficiency than the immobilized dye based kit (PROTBA-Sigma) in umbilical cord serum samples. Both the PROTIA-Sigma and 5185-Agilent kit maintained high depletion efficiency when used three consecutive times. Depletion by the PROTIA-Sigma Kit improved 2DE gel quality by reducing smeared bands produced by the presence of high abundance proteins and increasing the intensity of other protein spots. During image analysis using the identical detection parameters, 411 ± 18 spots were detected in crude serum gels, while 757 ± 43 spots were detected in depleted serum gels. Eight spots unique to depleted serum gels were identified by MALDI- TOF/TOF MS, seven of which were low abundance proteins.
The immunoaffinity based kits exceeded the immobilized dye based kit in high abundance protein depletion of umbilical cord serum samples and dramatically improved 2DE gel quality for detection of trace biomarkers.
- Protein Spot
- High Abundance Protein
- Depletion Method
- Depletion Process
- Depletion Efficiency
The fetal period is an important and special time in human life, in which the fetus grows quickly and develops dramatically. The umbilical cord blood makes contacts with all fetal tissues and is related to the physiological or pathological states of the fetus. Moreover, umbilical cord blood plays a critical role in transport of oxygen/carbon dioxide and other materials between mother and fetus through the placenta, thereby effecting how the intrauterine environment (maternal and placental factors) influences the fetus. Therefore, qualitative and quantitative changes of some umbilical cord serum proteins (i.e. α-fetoprotein, adiponectin and leptin) are widely used for clinical diagnosis and therapeutic monitoring of fetal or neonatal disorders .
Proteomics, a high flux approach in new protein discovery, is playing an increasingly important role in the development of novel biomarkers for various diseases . Previously, proteomics techniques have been extensively applied in the investigation of adult plasma/serum proteomes in normal and diseased states . More recently, increasing interest in umbilical cord proteomics has emerged, in order to search for novel biomarkers of fetal and neonatal diseases .
The first challenge in proteomics studies is sample preparation. For plasma/serum based proteomics research, the depletion of high abundance proteins is of great importance in sample preparation. In human serum, protein concentrations are found in an extremely wide range, with several kinds of highly abundant proteins (i.e. albumin and IgG) making up more than 80% of the total protein contained in the serum , while a number of important biomarkers are found only in trace amounts. High abundance proteins influence proteomics studies in two ways: Firstly, in 2DE gel based proteomics studies, low abundance proteins are likely to be masked by high abundance proteins on the gel. Secondly, the sample amount used for the study tends to be limited, and since highly abundant proteins completely dominate the protein content, detection of low abundance proteins becomes extremely difficult. Therefore, several depletion kits have been developed to remove highly abundant proteins in human plasma/serum [6–9] for use in further proteomics research. However, most of the depletion approaches have only been tested and evaluated in adult serum or plasma, and little data about their usage and efficiency in fetal or umbilical cord serum/plasma depletion was available.
Depletion kits remove highly abundant proteins by binding to specific sites on the proteins. However, some proteins (i.e. albumin) in fetal, neonatal and umbilical cord serum are structurally different from those in adult serum  and the depletion efficiency of a method varies when the method is applied in different sample types . Therefore, it comes to question whether the approaches which revealed high depletion efficiency in adult serum/plasma are adequate to remove highly abundant proteins in umbilical cord serum.
To the furthest of our knowledge, only two kits: ProteoPrep Top 20 protein immunoaffinity column (Sigma-Aldrich, Saint Louis, MO, USA)  and the Multiple affinity removal column system (Agilent, Santa Clara, CA, USA) , had been used for depletion of high abundance proteins from umbilical cord serum samples. These two kits were able to remove several highly abundant proteins from umbilical cord serum and were compatible with iTRAQ or LC-MS studies, respectively. However, the compatibility of these two kits with 2DE based proteomics studies and their depletion efficiencies remained untested.
The primary aim of the present study is to evaluate the efficiency of three commonly used commercial kits on depletion of high abundance proteins from umbilical cord serum, and to search for an effective and reproducible approach to umbilical cord serum sample preparation for further proteomics research.
Evaluation of depletion efficiency and reproducibility of each protein depletion kit using umbilical cord serum
Several approaches have been developed to deplete high abundance proteins from adult plasma/serum. However, their usage and efficiency of depletion of highly abundant proteins from fetal or umbilical cord serum/plasma remains unknown. To set up a high abundance protein depletion method suitable for umbilical cord serum, we evaluated the three most commonly used depletion kits, testing for depletion efficiency, reproducibility, and the yield of depleted serum.
It has been reported that the Multiple Affinity Removal System (5185, Agilent, Santa Clara, CA, USA) was able to remove six kinds of highly abundant proteins (including albumin, IgG, a1-antitrypsin, IgA, transferrin, and haptoglobin) from human serum and could be used 200 times, repeatedly. To investigate the depletion efficiency and reproducibility of the 5185-Agilent system, we ran the system three times consecutively using an HPLC system. The 5185-Agilent system was equilibrated according to the manual guidelines prior to each depletion process. Next, samples were concentrated by ultrafiltration and the depleted or bound proteins were analyzed by SDS-PAGE either separately or as a pooled sample. As shown in Figure 1C, albumin and IgG were almost completely removed by the 5185-Agilent column and this high efficiency was maintained when the column was run a second and third time. The column not only removed albumin and IgG, but also cleared four other high abundance proteins, namely a1-antitrypsin, IgA, transferrin, and haptoglobin from the serum. This result demonstrated the high efficiency and good reproducibility of the 5185-Agilent column during umbilical cord serum depletion.
The second immunoaffinity kit we tested was the Immunoaffinity Albumin and IgG Depletion kit (PROTIA, Sigma-Aldrich, Saint Louis, MO, USA). It has been reported that this kit was able to remove 95% of albumin and IgG in human serum, but no data about its reproducibility was available. To evaluate the depletion efficiency and reproducibility of the PROTIA-Sigma kit, we used the kit three times consecutively, with re-equilibration between each depletion process. As shown in Figure 1D, the PROTIA-Sigma Kit effectively removed most of the albumin and IgG from the umbilical cord serum (Figure 1D, Lane D1, D2 and D3) in the first, second and third depletion process, and the depletion efficiency of each process was similar (Figure 1D, Lane B1, B2 and B3). This result suggested that the PROTIA-Sigma Kit was not only effective to remove high abundance proteins from umbilical cord serum, but could also be used repeatedly.
Evaluation of yield for each protein depletion kit tested using umbilical cord serum
Besides depletion efficiency and repeatability, the protein yield post-depletion was another important factor regarding the compatibility of the depletion method with downstream analysis. Therefore, we measured the protein concentration of the depleted serum by Bradford Protein Assay (Bio-Rad, Hercules, CA, USA) to determine the protein yield after depletion by each of the kits.
Approximate Yield from Each Depletion Method
Load Volume (μl)
Yield Concentration (μg/μl)
Blue Albumin and IgG Depletion Kit (PROTBA, Sigma-Aldrich)
Multiple Affinity Removal System (5185, Agilent)
Immunoaffinity Albumin and IgG Depletion Kit (PROTIA, Sigma-Aldrich)
In summary, the immunoaffinity based methods exceeded the immobilized dye based method in depletion efficiency, and both immunoaffinity based methods have high reproducibility. Since the yield for the depleted serum by the PROTIA-Sigma immunoaffinity kit was high with no additional concentrating or ion extracting required, we chose this kit for analysis by 2D electrophoresis to further evaluate its compatibility with downstream proteomics studies and to investigate whether high abundance protein depletion improves serum protein profiling patterns in 2DE gels.
2DE of crude and depleted umbilical cord serum samples
Depletion of high abundance proteins is expected to improve the serum protein profiling pattern of 2DE gels by enabling visualization of protein spots that were previously masked by the highly abundant proteins and by increasing the low abundance protein load. However, whether the depleted serum can be directly used for 2DE based proteomics studies remains unknown since depleted serum contains additional ions which may influence isoelectric focusing (IEF). Therefore, to determine the compatibility of the depletion method with 2DE based proteomics, depleted umbilical cord serum samples from the PROTIA-Sigma kit were selected for analysis by 2D gel electrophoresis, using crude serum samples as comparison.
Image analysis using ImageMaster was performed on triplicate samples of crude and depleted serum 2DE gels. Since the protein patterns between crude and depleted serum gels were variable, matching was performed within groups. For the crude group, 411 ± 18 spots were detected while for the depleted group, 757 ± 43 spots were detected. The matching rate between gels in the crude serum group was 62.2 ± 4.3% and that in the crude group was 75.12 ± 3.9%.
MALDI-TOF/TOF MS identification of selected protein spots which were unique to the depletion gels.
Mascot MS/MS score
Sequence coverage (%)
Hematopoietic lineage cell specific protein
Tubulin alpha chain-like 3
Tropomyosin beta chain
In the present study, we have compared three commercially available depletion kits on umbilical cord serum depletion, regarding depletion efficiency, reproducibility, protein yield and compatibility with downstream proteomics research. Results have demonstrated that the immunoaffinity depletion kits exceeded the immobilized dye based kit in depletion efficiency when used on umbilical cord serum. The depleted umbilical cord serum produced by the Immunoaffinity Albumin and IgG Depletion kit (PROTIA, Sigma-Aldrich, Saint Louis, MO, USA) could be directly applied in isoelectric focusing (IEF) and improved 2DE gel quality for low abundance protein detection.
The first important aspect in evaluating a depletion kit is depletion efficiency. The PROTBA-Sigma Kit mainly contains Cibacron Blue and Protein A/G. Cibacron Blue has been reported to bind human serum albumin by interacting with the bilirubin-binding site(s) and the fatty acid-anion-binding sites . Protein A has been reported to bind the Fc portion of IgG, while Protein G binds to both the Fc and Fab portion of IgG . As a dye-based depletion kit, the PROTBA-Sigma kit demonstrated considerable depletion efficiency in adult plasma/serum in previous studies, but albumin in umbilical cord serum could not be completely removed by this kit in the present study. The low efficiency of this kit in umbilical cord serum depletion may be due to structural difference between fetal and adult albumins. In a previous study, Wallace S  identified that the structure of neonatal albumin (similar to fetal albumin) was different from adult albumin due to variable amino acid composition. In another study, Ingrid Miller et al  showed the affinity of Cibacron Blue F3GA, an immobilized dye matrix, was variable for albumin of different species due to the structural variations of the proteins. Therefore, based on the data from these two previous studies and the present study, we infer that structural alterations caused by amino acid variations of fetal albumin leads to the low interaction strength between fetal albumin and blue matrix in the PROTBA-Sigma kit.
Conversely, both immunoaffinity based kits, the 5185-Agilent kit and the PROTIA-Sigma kit, had higher efficiency in umbilical cord serum depletion. Although structurally different, fetal albumin is immunologically similar to adult albumin . Therefore, as expected, the immunoaffinity based depletion kits had comparable efficiency when applied to adult and umbilical cord serum depletion.
The second aspect when analyzing a depletion method is reproducibility. The protein amount used in proteomics studies is large with replicate experiments often required. Since the protein yield produced by a single depletion process is typically not enough for further analysis, the reproducibility of a kit is very important for preparation of a large scale sample. In a recent study on umbilical cord serum proteomics , the Multiple Affinity Removal System (Agilent, Santa Clara, CA, USA) was used to deplete high abundance proteins from umbilical cord serum. The one-dimensional SDS-PAGE analysis in this article demonstrated that the depletion efficiency was considerable, but reproducibility of the kit was not reported. Therefore, we extended this evaluation of the 5185-Agilent kit as well as the PROTIA-Sigma kit to determine reproducibility, in order to maximize the yield for further proteomics studies. Results from this study indicate that both immunoaffinity based kits had high reproducibility, with similar depletion efficiencies occurring after the columns were used for three consecutive repeat experiments.
The third factor in assessing a depletion kit is protein yield. Since the sample volume and protein amount for IEF should both be within fixed ranges, appropriate protein concentrations of depleted serum is required for 2DE based proteomics. According to previous studies, the protein concentration of the loading sample for silver stained 2DE gels should not be less than 0.5 μg/μl, and the concentration of the loading sample for Coomassie Blue stained 2DE gels should be even higher. Therefore, the depleted sera by the PROTBA-Sigma and PROTIA-Sigma kits, as well as the concentrated sera produced by the 5185-Agilent kit were all within the appropriate protein concentration range. Both the serum load and the protein yield were highest for the PROTIA-Sigma kit, indicating that it was most suitable for large scale protein preparation. It should be noted that although the protein yield percentage of the PROTBA-Sigma Kit was in fact highest, this was likely due to contamination by albumin and IgG that was not depleted.
The fourth and most important factor in evaluating a depletion kit is whether the resulting serum can be used in downstream proteomics studies and if it can improve the quality of these studies. The PROTBA-Sigma kit was excluded due to its low depletion efficiency and so the choice remained between the two immunoaffinity kits. Of the two kits, the PROTIA-Sigma kit was chosen for two reasons: firstly, the usage of the 5185-Agilent kit in umbilical cord serum had been previously reported and so if the PROTIA-Sigma kit proved successful, it would provide a new choice for researchers. Secondly, the depleted serum from the PROTIA-Sigma kit could be used for isoelectric focusing (IEF) directly since the wash solution contained fewer ions. Depletion improved 2DE gel quality by two aspects. Firstly, since the majority of albumin and IgG were depleted, protein spots which were masked in the crude gels became detectable. Secondly, the intensity of many low abundance proteins increased because they now represented a larger proportion of the total sample amount.
To date, many immunoaffinity based depletion kits have been designed for removal of two, six, twelve, or twenty types of highly abundant proteins from serum. Therefore, another question when choosing a depletion kit for serum/plasma proteomics is how many kinds of high abundance proteins should be depleted . The choice of depletion method depends on the design of the study, the experimental method, and the balance between the removal of highly abundant proteins and the loss of associated low abundance proteins. Albumin and IgG represent about 80% of the total protein content in umbilical serum, so removal of albumin and IgG is expected to increase the low abundance protein load by approximately 4-5 times. In the present study, we identified eight protein spots unique to depleted serum gels, most of them low abundance proteins. Therefore, removal of the two most abundant proteins (albumin and IgG) is adequate for detection of primarily low abundance biomarkers. However, removal of more kinds of highly abundant proteins may be needed for further enrichment of some proteins naturally found in trace amounts. In that case, the 5185-Agilent system may play an important role, since it can remove six kinds of high abundance proteins with high specificity .
Our study compared three high abundance protein depletion kits on umbilical cord serum sample preparation for proteomics, regarding their depletion efficiency, reproducibility, yield and compatibility with downstream proteomics studies. The immunoaffinity based depletion methods exceeded the immobilized dye based method in depletion efficiency. Both of the immunoaffinity based kits, PROTIA-Sigma and 5185-Agilent revealed high reproducibility and appropriate protein yield for further proteomics analysis (although an additional protein concentrating step was required for the 5185-Agilent kit). Based on 2DE and MS results, the PROTIA-Sigma Kit dramatically improved 2DE gel quality by increasing low abundance protein intensity, and thus serves as a useful tool in novel biomarker discovery.
Umbilical cord venous blood samples were provided by two healthy pregnant women after placenta delivery. Venous blood samples from two healthy adults were chosen as control for comparison of depletion efficiency between adult serum and umbilical cord serum. The samples were collected in sterile vacuum blood collection tubes and placed at room temperature (25°C) for one hour to allow the blood to clot. After blood coagulation, sera were separated by centrifugation at 720 g for 15 min at 4°C, frozen in aliquots of 100 μl, and stored at -80°C until analysis. The study was approved by the research ethical committee of The First Affiliated Hospital of Sun Yat-sen University and informed consent was provided by all volunteers.
Depletion of high abundance proteins from umbilical cord serum by three kits
Three depletion kits were used in the present study: the ProteoPrep Blue Albumin and IgG Depletion Kit (PROTBA, Sigma-Aldrich, Saint Louis, MO, USA), the Agilent Multiple Affinity Removal System (5185, Agilent, Santa Clara, CA, USA) and the ProteoPrep Immunoaffinity Albumin and IgG Depletion Kit (PROTIA, Sigma-Aldrich, Saint Louis, USA).
For the PROTBA-Sigma Kit, 25 μl of serum was loaded onto the equilibrated column and incubated two consecutive times and the "twice depleted" serum was collected. Then, the bound proteins (albumin and IgG) were eluted by the Protein Extraction Reagent Type 4.
For the 5185-Agilent column, 20 μl of serum was diluted in 80 μl Buffer A prior to completion of the depletion process. After column equilibration, 100 μl of diluted serum was loaded onto the column at a flow rate of 250 μl/min. Buffer A was then injected at a flow rate of 250 μl/min and fractions between 1.5-4.5 min were collected. Next, bound proteins were eluted with Buffer B at a flow rate of 1000 μl/min. Buffer A was used to regenerate the column for further use.
For the PROTIA Kit, 50 μl of serum was diluted in 50 μl of Equilibration Buffer before performing the depletion process. After column equilibration, 100 μl of diluted serum was loaded onto the column and incubated two consecutive times. The "twice depleted" serum was then collected and the bound proteins were eluted by Protein Extraction Reagent Type 4.
Total protein concentration of crude serum, depleted samples, and eluted proteins were determined by Bradford protein assay according to the manufacturer's instructions (Bio-Rad, Hercules, CA, USA), using bovine serum albumin (BSA) as a standard. The depleted and eluted proteins from 5185-Agilent kit were concentrated using 5000 Da molecular mass cut-off centrifugal concentrators (Millipore, Billerica, MA, USA) prior to determination of protein concentration. Samples were then stored at -80°C until further analysis.
The depletion efficiency of each approach was evaluated by SDS-PAGE. Ten micrograms of crude, depleted, and bound proteins from each approach were loaded into each lane of 12% resolving and 4% stacking polyacrylamide gels (GE Healthcare, Waukesha, WI, USA) and electrophoresed through a Bio-Rad system (Bio-Rad, Hercules, CA, USA) using the Laemmli SDS buffering system (25 mM Tris-base, 192 mM glycine, 0.1%SDS). The gels were stained with Coomassie Blue (GE Healthcare, Waukesha, WI, USA) overnight according to the manufacturer's instructions.
Two-dimensional Gel Electrophoresis
For 2DE analysis, 150 μg of depleted or crude umbilical cord serum protein samples were diluted in sample buffer consisting of 50 mM Tris-HCl (pH 8.5), 7 M urea, 2 M thiourea, 2% CHAPS, 0.3% dithiothreitol (DTT), 0.5% IPG buffer (pH 4-7 linear), and 10 μl of a protease inhibitor mixture (Sigma-Aldrich, Saint Louis, MO, USA) to a final volume of 450 μl. Protein samples were applied on immobilized pH 4-7 linear gradient IPG strips (24 cm) (Bio-Rad, CA, USA) and active rehydration was performed at 30 V for 6 h and 60 V for 6 h. Focusing was performed using an Ettan IPGphor III IEF system (GE Healthcare, Waukesha, WI, USA) at 200 V for 2 h, 500 V for 2 h, 1000 V for 2 h, 5000 V for 2 h, after which the voltage was gradually increased to 10000 V for 85000 Vhs and kept at 500 V for 5 h.
After focusing, strips were equilibrated for 15 min in 75 mM Tris-HCl (pH 8.8), 6 M urea, 2% w/v SDS, 29.3% v/v glycerol, and 1.0% DTT, followed by a 15 min incubation in the same buffer containing 2.5% iodoacetamide in place of DTT. Second-dimension electrophoresis was performed on a 12.5% polyacrylamide gel, using an Ettant DALT Six system (GE Healthcare, Waukesha, WI, USA). Each gel was run at 2 w for 1 h at 15°C, and then increased to 15 w until the tracking dye migrated to within 1 cm of the bottom of the gel.
Protein Visualization and Computer Analysis of Protein spots
2D gels were fixed in 50% methanol (containing 5% acetic acid) for 2 h and visualized by silver staining using a modified protocol of Grit Nebrich et al . Briefly, after washing three times with distilled water, the gels were sensitized with sodium thiosulphate (0.02%w/v) for 2 min, and then washed twice (one minute each) with distilled water. Next, the gels were incubated in 0.1% silver nitrate solution for 30 minutes. After 3 rinses, the gels were developed with 2% sodium carbonate solution (containing 0.05% formalin) for 2-10 min and terminated with 5% acetic acid. After incubation in 5% acetic acid for 20 min, the gels were transferred into distilled water and scanned using the ImageScanner system (GE Healthcare, Waukesha, WI, USA) combined with LabScan software (GE Healthcare, Waukesha, WI, USA). All gel images were analyzed using ImageMaster 2D Platinum software (GE Healthcare, Waukesha, WI, USA). Three 2D gels from the depleted sample and three from the crude serum were analyzed. Gel images from each group were edited, and spots were matched. A unique identification number was assigned to matching spots on different gels. Normalization of the spot intensities was conducted according to the total optical density of the gel.
In-gel tryptic digestion
Spots from 2DE gels selected for further analysis were cut using a blade and gel pieces were transferred to microfuge tubes. After rinsing with distilled water and destaining with potassium ferricyanide and sodium thiosulfate, the gel pieces were dehydrated in 100% acetonitrile. 2 μL (25 ng/μl) of modified porcine trypsin in 25 mM ammonium bicarbonate, pH 8, was added to each sample and incubated at 37°C overnight. The trypsin solutions were collected and the remaining peptides were extracted from the gel pieces by incubation in 0.1% Trifluoroacetic acid/60% acetonitrile for 15 min prior to drying in a vacuum centrifuge.
MALDI-MS and MS/MS analysis
MALDI-TOF/TOF MS measurements were performed on a Bruker Ultraflex III MALDI-TOF/TOF MS (Bruker Daltonics, Leipzig, Germany) operating in reflectron mode with 20 kV accelerating voltage and 23 kV reflecting voltage. A saturated solution of α-cyano-4-hydroxycinnamic acid in 50% acetonitrile and 0.1% trifluoroacetic acid was used as the matrix. One microliter of the matrix solution and sample solution at a ratio of 1:1 was applied onto the Score384 target well. By routine, a standard peptide calibration mix in the mass range 800-3200 Da (Bruker Daltonics, Leipzig, Germany) was analyzed for external calibration of the mass spectrometer. The calibration mix contained: Angiotensin II, Angiotensin I, Substance P, Bombesin, ACTH clip 1-17, ACTH clip 18-39, and Somatostatin 28. A series of eight samples were spotted around one external calibration mixture. The SNAP algorithm (S/N threshold: 5; Quality Factor Threshold: 30) in FlexAnalysis 3.0 was used to pick up the 100 most prominent peaks in the mass range m/z 700-4000. The subsequent MS/MS analysis was performed in a data-dependent manner, and the 5 most abundant ions fulfilling certain preset criteria (S/N higher than 3 and Quality Factor higher than 30) were subjected to high energy CID analysis. The collision energy was set to 1 keV, and nitrogen was used as the collision gas.
Peptide mass fingerprints (PMFs) were searched using the program Mascot 2.1 (Matrix Science Ltd) against the SwissProt database (version 20091028, 510076 sequences). The search parameters were as follows: trypsin digestion with one missed cleavage; carbamidomethyl modification of cysteine as a fixed modification and oxidation of methionine as a variable modification; peptide tolerance maximum, ±0.3 Da; MS/MS tolerance maximum, ±50 ppm; peptide charge, +1; monoisotopic mass. p < 0.05 is for a local PMF search. For unambiguous identification of proteins, more than 5 peptides must be matched for a PMF search.
Acknowledgements and Funding
We thank Dr. Shawn Shun-Cheng Li for critically reviewing the manuscript. This work was supported by Science and Technology Planning Project of Guangdong Province, China (No. 2009B03081099, to Zi-lian Wang) and Scholarship Award for Excellent Doctoral Student (to Bin Liu and Zi-lian Wang as supervisor) granted by Ministry of Education of China.
- Kyriakakou M, Malamitsi-Puchner A, Militsi H, Boutsikou T, Margeli A, Hassiakos D, Kanaka-Gantenbein C, Papassotiriou I, Mastorakos G: Leptin and adiponectin concentrations in intrauterine growth restricted and appropriate for gestational age fetuses, neonates, and their mothers. Eur J Endocrinol 2008, 158: 343–348. 10.1530/EJE-07-0692PubMedView ArticleGoogle Scholar
- Anderson NL, Anderson NG: The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics 2002, 1: 845–867. 10.1074/mcp.R200007-MCP200PubMedView ArticleGoogle Scholar
- Song HJ, Zhang P, Guo XJ, Liao LM, Zhou ZM, Sha JH, Cui YG, Ji H, Liu JY: The proteomic analysis of human neonatal umbilical cord serum by mass spectrometry. Acta Pharmacol Sin 2009, 30: 1550–1558. 10.1038/aps.2009.140PubMed CentralPubMedView ArticleGoogle Scholar
- Page NM, Kemp CF, Butlin DJ, Lowry PJ: Placental peptides as markers of gestational disease. Reproduction 2002, 123: 487–495. 10.1530/rep.0.1230487PubMedView ArticleGoogle Scholar
- Urbas L, Brne P, Gabor B, Barut M, Strlic M, Petric TC, Strancar A: Depletion of high-abundance proteins from human plasma using a combination of an affinity and pseudo-affinity column. J Chromatogr A 2009, 1216: 2689–2694. 10.1016/j.chroma.2008.10.104PubMedView ArticleGoogle Scholar
- Tanaka Y, Akiyama H, Kuroda T, Jung G, Tanahashi K, Sugaya H, Utsumi J, Kawasaki H, Hirano H: A novel approach and protocol for discovering extremely low-abundance proteins in serum. Proteomics 2006, 6: 4845–4855. 10.1002/pmic.200500774PubMedView ArticleGoogle Scholar
- Bellei E, Bergamini S, Monari E, Fantoni LI, Cuoghi A, Ozben T, Tomasi A: High-abundance proteins depletion for serum proteomic analysis: concomitant removal of non-targeted proteins. Amino Acids, in press.Google Scholar
- Govorukhina NI, Reijmers TH, Nyangoma SO, van der Zee AG, Jansen RC, Bischoff R: Analysis of human serum by liquid chromatography-mass spectrometry: improved sample preparation and data analysis. J Chromatogr A 2006, 1120: 142–150. 10.1016/j.chroma.2006.02.088PubMedView ArticleGoogle Scholar
- Björhall K, Miliotis T, Davidsson P: Comparison of different depletion strategies for improved resolution in proteomic analysis of human serum samples. Proteomics 2005, 5: 307–317. 10.1002/pmic.200400900PubMedView ArticleGoogle Scholar
- Wallace S: Altered plasma albumin in the newborn infant. Br J Clin Pharmacol 1977, 4: 82–85.PubMed CentralPubMedView ArticleGoogle Scholar
- Miller I, Gemeiner M: An electrophoretic study on interactions of albumins of different species with immobilized Cibacron Blue F3G A. Electrophoresis 1998, 19: 2506–2514. 10.1002/elps.1150191425PubMedView ArticleGoogle Scholar
- Colquhoun DR, Goldman LR, Cole RN, Gucek M, Mansharamani M, Witter FR, Apelberg BJ, Halden RU: Global screening of human cord blood proteomes for biomarkers of toxic exposure and effect. Environ Health Perspect 2009, 117: 832–838.PubMed CentralPubMedView ArticleGoogle Scholar
- Leatherbarrow RJ, Dean PD: Studies on the mechanism of binding of serum albumins to immobilized cibacron blue F3G A. Biochem J 1980,189(1):27–34.PubMed CentralPubMedGoogle Scholar
- Andrew SM, Titus JA: Purification of immunoglobulin G. Curr Protoc Immunol 2001, Chapter 2: Unit 2.7.PubMedGoogle Scholar
- Gitzelmann-Cumarasamy N, Gitzelmann R, Wilson KJ, Kuenzle CC: Fetal and adult albumins are indistinguishable by immunological and physicochemical criteria. Proc Natl Acad Sci USA 1979, 76: 2960–2963. 10.1073/pnas.76.6.2960PubMed CentralPubMedView ArticleGoogle Scholar
- Roche S, Tiers L, Provansal M, Seveno M, Piva MT, Jouin P, Lehmann S: Depletion of one, six, twelve or twenty major blood proteins before proteomic analysis: the more the better? J Proteomics 2009, 72: 945–951. 10.1016/j.jprot.2009.03.008PubMedView ArticleGoogle Scholar
- Bellei E, Bergamini S, Monari E, Fantoni LI, Cuoghi A, Ozben T, Tomasi A: High-abundance proteins depletion for serum proteomic analysis: concomitant removal of non-targeted proteins. Amino Acids 2011,40(1):145–56. 10.1007/s00726-010-0628-xPubMedView ArticleGoogle Scholar
- Nebrich G, Herrmann M, Sagi D, Klose J, Giavalisco P: High MS-compatibility of silver nitrate-stained protein spots from 2-DE gels using ZipPlates and AnchorChips for successful protein identification. Electrophoresis 2007,28(10):1607–14. 10.1002/elps.200600656PubMedView ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.